Literature DB >> 30974045

Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.

Nobuharu Tamaki1,2, Mayu Higuchi1, Masayuki Kurosaki1, Sakura Kirino1, Leona Osawa1, Keiya Watakabe1, Wan Wang1, Mao Okada1, Takao Shimizu1, Kenta Takaura1, Hitomi Takada1,2, Shun Kaneko1, Yutaka Yasui1, Kaoru Tsuchiya1, Hiroyuki Nakanishi1, Jun Itakura1, Yuka Takahashi1, Nobuyuki Enomoto2, Namiki Izumi1.   

Abstract

Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important, and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct-acting antivirals were included. Magnetic resonance elastography (MRE) and serum fibrosis markers were measured 12 weeks after the end of treatment, and the subsequent HCC development was examined. The mean observation period was 26.4 ± 7.9 months, and 24 patients developed HCC. Area under the receiver operating characteristic curve of liver stiffness by MRE, Wisteria floribunda agglutinin-positive mac-2 binding protein and FIB-4 for predicting HCC within 3 years was 0.743, 0.697 and 0.647, respectively. The 1/2/3-year rates of HCC development in patients with liver stiffness ≥3.75 KPa were 6.6%, 11.9% and 14.5%, whereas they were 1.4%, 2.5% and 2.5% in patients with liver stiffness <3.75 KPa (P < 0.001). Multivariate analysis revealed that liver stiffness ≥3.75 was an independent predictive factor for HCC development (hazard ratio, 3.51; 95% confidence interval, 1.24-9.99). In subgroup analysis, there were 132 patients who were <73 years old and had liver stiffness <3.75 KPa, and no HCC development was observed in these patients. Diagnostic accuracy for predicting HCC development was higher in MRE than serum fibrosis markers and measurement of liver stiffness by MRE could identify patients with high and low risk of HCC development after SVR.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  FIB-4; Wisteria floribunda agglutinin-positive mac-2 binding protein; chronic hepatitis C; hepatocellular carcinoma; magnetic resonance elastography

Year:  2019        PMID: 30974045     DOI: 10.1111/jvh.13103

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  8 in total

Review 1.  Advances in Magnetic Resonance Elastography of Liver.

Authors:  Jiahui Li; Sudhakar Kundapur Venkatesh; Meng Yin
Journal:  Magn Reson Imaging Clin N Am       Date:  2020-06-06       Impact factor: 2.266

2.  Magnetic resonance elastography can predict the development of hepatocellular carcinoma: a meta-analysis and systematic review.

Authors:  Lianglong Wu; Junying Bi; Liangjin Liu; Yanni Zeng
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 3.  Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Kaoru Tsuchiya; Namiki Izumi
Journal:  J Med Ultrason (2001)       Date:  2021-06-24       Impact factor: 1.314

4.  Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Koji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Rohit Loomba; Namiki Izumi
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

Review 5.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

6.  Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.

Authors:  Leona Osawa; Nobuharu Tamaki; Masayuki Kurosaki; Sakura Kirino; Keiya Watakabe; Wan Wang; Mao Okada; Takao Shimizu; Mayu Higuchi; Kenta Takaura; Hitomi Takada; Shun Kaneko; Yutaka Yasui; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Nobuyuki Enomoto; Namiki Izumi
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

7.  Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Kouji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Toshifumi Tada; Shinichiro Nakamura; Satoshi Yasuda; Hidenori Toyoda; Rohit Loomba; Namiki Izumi
Journal:  Hepatol Commun       Date:  2021-10-22

8.  Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.

Authors:  Kazuhito Kawata; Masanori Atsukawa; Kazuyoshi Ohta; Takeshi Chida; Hidenao Noritake; Taeang Arai; Katsuhiko Iwakiri; Satoshi Yasuda; Hidenori Toyoda; Tomomi Okubo; Atsushi Hiraoka; Tsunamasa Watanabe; Haruki Uojima; Akito Nozaki; Joji Tani; Asahiro Morishita; Fujito Kageyama; Yuzo Sasada; Masamichi Nagasawa; Masahiro Matsushita; Tatsuki Oyaizu; Shigeru Mikami; Tadashi Ikegami; Hiroshi Abe; Kentaro Matsuura; Yasuhito Tanaka; Akihito Tsubota
Journal:  Hepatol Commun       Date:  2022-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.